Neutrophil lymphocyte and platelet lymphocyte ratios are associated with disease activity in rheumatoid arthritis

NLR and PLR are reliable markers in rheumatoid arthritis

Senem Şaş
Department of Physical Medicine and Rehabilitation, Ahi Evran University Training and Research Hospital, Kirsehir, Turkey

Abstract

Aim: The aim of this study is to determine the relationship between Neutrophil to Lymphocyte (NLR) and Platelet to Lymphocyte (PLR) ratios in patients with Rheumatoid Arthritis (RA) and Disease Activity Score-28 (DAS28) and Rheumatoid Arthritis Quality of Life (RAQol). Material and Method: One hundred twenty-five RA patients and 105 healthy controls were enrolled in the study. Patients were assessed and PLR, NLR, and DAS28, RAQol values were calculated. Disease activity was calculated by DAS28 and quality of life was examined by RAQol, HAQ (Health Assessment Questionnaire). Results: NLR (2.4 ± 1.9) and PLR (155.2 ± 82.3) value was significantly higher (p < 0.05) in RA. Positive correlation was observed between the two groups between DAS 28 with age, morning stiffness, VAS pain assessment, RF, ESR, CRP, NLR, PLR and swollen and tender joint number (p < 0.05) Significant negative correlation was observed between DAS 28 and hemoglobin, RBC, lymphocyte, monocyte % value (p < 0.05). There was no significant correlation between DAS28 and RAQol, HAQ (p>0.05). Discussion: This study presents that NLR and PLR are associated with disease activity in patients with RA. NLR and PLR values can be assessed as an additional inflammatory marker in patients with RA.

Keywords

DAS-28; Neutrophil; Lymphocyte; Thrombocyte; Rheumatoid Arthritis, Hemogram
Introduction
Rheumatoid Arthritis (RA) is the most common inflammatory systemic disease all over the world. Its incidence is about 1%. Genetic and environmental factors play role in inanition and activation of RA, RA, not only affects joints but also extra-articular involvement is common [1-2]. This systemic disease can present major organ involvement. RA is one of the leading inflammatory diseases that reported mainly in females. In the nature of disease synovial inflammation leads to erosion and deformity in joints [2]. At baseline and during follow-up patients with RA is assessed by clinic examination including number of tender joint count (TJC), number of swollen and laboratory findings. And also visual analog scale (VAS), Disease activity score of 28 joints (DAS-28) is measured [3].

Hemogram, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are the most common laboratory tests in routine procedure. Chronic disease anemia is the most common laboratory finding. Anemia is associated with the disease activity in patients with RA. Hemogram also known as complete blood count is an available, cheap method that includes parameters of inflammatory, cardiovascular and oncologic diseases [4,5].

In the pathogenesis of RA, T and B lymphocytes, mast cells and neutrophils play an important role. Thus, it has been suggested that neutrophil/lymphocyte ratio (NLR) is a good indicator of systemic inflammation. And also the number of platelets in RA is high even in the early stages. Additionally, mean platelet volume (MPV) and platelet distribution width (PDW) are helpful markers [6-8].

Previous studies mentioned that NLR, PLR (platelet to lymphocyte), MPV and PDW are useful markers to measure systemic inflammation in RA [9-11]. But the data on these parameters is limited.

In this study, we aimed firstly, to assess NLR and PLR ratios and disease activity and quality of life in patients with RA. Secondly, the aim of this study is to describe hemogram parameters and its relation to RA.

Material and Methods
This study was performed between September 2017 and March 2018 and designed in Ahi Evran University Training and Research Hospital. The study design was performed retrospectively. One hundred twenty-five patients with RA, assessed by the diagnostic criteria of the American College of Rheumatology (ACR) 2010/ European League Against Rheumatism (EULAR) 2010 and a control group of 105 and gender-matched healthy subjects were enrolled in the study. Control group consists of healthy subjects from hospital staff. Demographic and clinical features were recorded. Routine tests including hemogram, ESR, CRP, Rheumatoid Factor (RF), Visual Analog Scale (VAS) (0-10), DAS28 and Larsen Score, swelling joint number, tender joint number, deformity, Rheumatoid Arthritis quality of life (RAQoL), Health Assessment Questionnaire (HAQ) were noted. Hemoglobin, Platelet, WBC (white blood cell), RBC (red blood cell), HCT (hemotocrite)

MCV (Mean corpuscular volume), MCH (Mean corpuscular hemoglobin), MCHC (mean corpuscular hemoglobin concentration), RDW (red cell distribution), Neutrophil % (neutrophil percentage), Monocyte % (monocyte percentage), Monocyte % (monocyte percentage), eosinophil % (eosinophil percentage), basophil % (basophil percentage), Neutrophil, lymphocyte, NLR, PLR, Eosinophil, Monocyte, Basophil, MPV (Mean platelet volume), PCT (plateletcrit), PDW values were recorded.

DAS28 were calculated by examination of 28 joints, ESR, patient VAS (0-10). Where O = best and 10 = worst, and both swollen and tender joint number. DAS28 scores is defined high (> 5.1), moderate (3.2<5,1), slightly active disease (≤ 3.2 - > 2.6) and remission (≤ 2.6) respectively [12].

RAQoL is assessed in patients with RA to examine quality of life. It includes 30 questions with a yes/no (1/0) response [13]. HAQ is calculated for general health in RA [14].

Patients with uncontrolled hypertension and diabetes mellitus, hepatic, cardiac, renal insufficiency and decompensated obstructive pulmonary disease were excluded. Patients under corticosteroid treatment were also excluded. All measurements were taken by the same physician (SS). All patients received medical immunosuppressive treatment.

Written informed consent was obtained. The study was approved by the local ethics committee and in accordance with Helsinki Declaration. (Approval number: 2017-17/203).

Statistical analysis
Mean, standard deviation, median lowest, highest, frequency and ratio values were used in the descriptive statistics of the data. The distribution of the variables was measured by the Kolmogorov-Smirnov test. Independent sample t-test and Mann-Whitney U test were used in the analysis of quantitative independent data. Chi-square test was used in the analysis of qualitative independent data. Spearman correlation analysis was applied for correlation analysis using SPSS 22.0 program.

Results
The age and sex distribution of the patients in the case and control groups did not differ significantly (p > 0.05) (Table 1). In the case group, hemoglobin value, RBC value, HCT value, lymphocyte% value, lymphocyte value, MPV value, PCT value were significantly lower than in the control group (p < 0.05). Such values as RBC value, MCV, MCH, RDW, NLR were significantly higher (p < 0.05) than PLR value in control group. In the case and control group, platelet value, WBC, MCHC, neutrophil, monocyte %, eosinophil % , basophil, neutrophil %, eosinophil, monocyte, basophil, PDW (p > 0.05) did not differ (Table 1). The clinical features of RA are given in Table 2.

Positive correlation was observed between the two groups between DAS 28 with age, morning stiffness, VAS pain assessment, RF, ESR, CRP, NLR and PLR and swollen and tender joint number (p < 0.05). Significant negative correlation was observed between DAS 28 and hemoglobin, RBC, lymphocyte, monocyte% value (p < 0.05). Significant correlation between DAS 28 and BMI, disease duration, platelet, WBC, HCT, MCV, MCH, MCHC, RDW, eosinophil%, basophil%, neutrophil, lymphocyte, eosinophil, monocyte, basophil, MPV, PCT, PDW were not observed (p > 0.05) (Table 3).

Nlr and Plr are reliable marker in rheumatoid arthritis
Table 1. Clinical and demographic features of Rheumatoid Arthritis and Healthy Control

| Patients (Rheumatoid Arthritis) | Controls | p      |
|---------------------------------|----------|--------|
| Age 56.1 ± 12.5                 | 57.1 ± 11.6 | 0.515  t |
| Sex Women 95                     | 76.6%     | 79     | 75.2% | 0.808 X |
| Men 29                          | 23.4%     | 26     | 24.8% |        |
| Hemoglobin (g/dL) 13.2 ± 1.62.5 | 13.8 ± 1.5 | 1.5    | 0.008 m |
| Platelet (10^12 u/L) 291.2 ± 95.4 | 269.0 ± 70.9 | 0.158 m |
| WBC (10^3 u/L) 7.4 ± 2.4         | 7.7 ± 1.6 | 1.050 m |
| RBC (10^6 u/L) 5.0 ± 1.4         | 4.9 ± 0.5 | 0.010 m |
| HCT (%) 39.7 ± 5.3              | 41.9 ± 4.2 | 0.001 m |
| MCV (fL) 87.0 ± 8.2              | 86.0 ± 4.9 | 0.028 m |
| MCHC (g/dL) 32.7 ± 1.5           | 32.8 ± 1.1 | 0.935 m |
| MPV (fL) 28.7 ± 3.3              | 28.3 ± 2.2 | 0.036 m |
| RDW (%) 32.7 ± 1.5               | 32.8 ± 1.1 | 0.935 m |
| Neutrophil % 14.9 ± 2.3          | 13.6 ± 1.0 | 0.001 m |
| Lymphocyte % 29.1 ± 8.4          | 31.5 ± 7.7 | 0.016 m |
| Monocyte % 7.6 ± 2.7             | 7.4 ± 1.9 | 0.970 m |
| Eosinophil % 2.4 ± 1.5           | 2.1 ± 1.5 | 0.089 m |
| Basophil % 0.8 ± 0.5             | 0.7 ± 0.3 | 0.221 m |
| Neutrophil (10^3 u/L) 5.1 ± 6.2  | 4.5 ± 1.3 | 0.563 m |
| Lymphocyte (10^3 u/L) 2.5 ± 3.3  | 2.9 ± 3.6 | 0.000 m |
| NLR 2.4 ± 1.9                    | 2.0 ± 1.1 | 0.017 m |
| Eosinophil (10^3 u/L) 0.47 ± 0.84| 0.24 ± 0.32| 0.165 m |
| Monocyte (10^3 u/L) 0.83 ± 1.66  | 0.57 ± 0.17| 0.078 m |
| Basophil (10^3 u/L) 0.1 ± 0.2    | 0.1 ± 0.31| 0.000 m |
| MPV (fL) 9.0 ± 1.2               | 10.2 ± 1.1| 0.000 m |
| PCT (%) 0.25 ± 0.08              | 0.27 ± 0.07| 0.006 m |
| PDW (FL) 12.1 ± 2.4              | 12.5 ± 2.5| 0.415 m |
| PLR 155.2 ± 82.3                 | 117.7 ± 48.1| 0.000 m |

1 t-test / X Mann-Whitney u test / Chi-square test

Table 2. Clinical features of Rheumatoid Arthritis

| N | % |
|---|---|
| Height (cm) | 157.4 ± 27.3 |
| Weight (kg) | 74.0 ± 15.0 |
| BMI (body mass index) | 0.1 ± 0.0 |
| Disease duration (years) | 8.1 ± 7.6 |
| Morning Stiffness (hours) | 24.6 ± 23.9 |
| VAS Pain (0-10) | 4.9 ± 2.4 |
| Onset joint involvement | Polyarticular 46/ 37.1% |
| | Oligoarticular 78/ 62.9% |
| DAS28 | 3.5 ± 1.4 |
| Remission | 32/ 25.8% |
| Low | 20/ 16.1% |
| Moderate | 58/ 46.8% |
| High Activity | 14/ 11.3% |
| Deformity | None 85/ 68.5% |
| | Swan Neck 16/ 12.78% |
| | Thumb Z Deformity 2/ 0.12% |
| | Ulnar Deviation 22/ 17.7% |
| | Rheumatoid Nodule 9/ 7.3% |

Discussion

This study suggests that hemoglobin, RBC, HCT, MCV, MCH, RDW, lymphocyte, NLR, MPV, PCT and PLR are significantly different in the RA group. While NLR and PLR are significantly higher, MPV is lower in patients with RA. Additionally, NLR, RAQoL, and PLR are associated with disease activity in patients with RA. But, we did not note any correlation between NLR and PLR with RAQoL. And also, neutrophil and platelet levels were not different from the control group.

Since past decades hemoglobin is assessed as a routine inflammatory test. Neutrophils are the leading elements in joint and synovial inflammation in patients with RA. And bone marrow is the main source of neutrophils [15].

It has been shown during systemic inflammation neutrophilia, leukocytosis, lymphopenia, thrombocytosis and elevated acute-phase reactants, TNF-α, IL-6, IL-8, procalcitonin are observed. ESR and CRP are simple and cheap biomarkers in systemic inflammation, but they are not specific. But also, measurements of proinflammatory cytokines are exhausting and precious [16]. Serum of patients with RA is expected to have neutrophilia and lymphopenia. Although neutrophilia is explained by systemic inflammation, the cause of lymphopenia still cannot be understood [17]. In one article, lymphopenia has been reported to have a reduced number of T cells with 15% induration of RA but with a normal number of B-cells. The reduction in T-cell count in the study was reported to be caused by T-cell infiltrating the synovial membrane. The range of neutrophil and platelet levels was normal in RA because patients were receiving medical treatment [18].

The association between NLR and PLR in several diseases including cardiovascular, infectious and oncological disease has been shown [4,5]. It has been suggested that activated platelets lead to chronic inflammation which is related with atherogenesis [19].

In a study performed by Uslu et al, it was reported that NLR and PLR correlated with disease activity [20]. Furthermore, Kilic et al. noticed that NLR and PLR levels are correlated with disease activity but not with RDW [21]. Tekeoglu et al. suggested that NLR is associated with disease activity. And also they noted that platelet count is associated with disease activity in RA, but they didn’t measure PLR levels [22]. In this study, while NLR and PLR were associated with DAS28, but no correlation was observed between RDW and DAS28.

In RA patients, NLR has been reported to be a good indicator of response to tocilizumab treatment [23]. In a review of the treatment effect on laboratory parameters in Rigby et al. in RA patients, they concluded that all treatments, including biological agents, reduced serum neutrophil and platelet levels [24]. Koizumi et al. emphasized that NLR shows efficacy of biological agents, reduced serum neutrophil and platelet levels [24].

In a study performed by Uslu et al, it was reported that NLR and PLR correlated with disease activity [20]. Furthermore, Kilic et al. noticed that NLR and PLR levels are correlated with disease activity but not with RDW [21]. Tekeoglu et al. suggested that NLR is associated with disease activity. And also they noted that platelet count is associated with disease activity in RA, but they didn’t measure PLR levels [22]. In this study, while NLR and PLR were associated with DAS28, but no correlation was observed between RDW and DAS28.

In RA patients, NLR has been reported to be a good indicator of response to tocilizumab treatment [23]. In a review of the treatment effect on laboratory parameters in Rigby et al. in RA patients, they concluded that all treatments, including biological agents, reduced serum neutrophil and platelet levels [24].

Koizumi et al. emphasized that NLR shows efficacy of biological treatments but is not a predictor of biological agent treatment [25]. The results of this study confirm the literature. But, none of the patients were receiving biological agent treatment. The association of MPV levels with platelets is well known. Proinflammatory cytokines suppress bone marrow, leading to a reduction in platelet volume. Kısacık et al. found low levels of MPV in the RA group [10]. In addition, Gasparian et al. reported that the MPV levels were elevated during TNF-alpha blockade treatment [26]. Also, Yazıcı et al. reported that MPV levels are
correlated with disease activity in RA [9]. In this study, MPV levels were found to be low in the RA group but not in the relation to disease activity.

A report from Japan suggested that STEAP4 [Six-transmembrane epithelial antigen of prostate 4] expressed by neutrophils and monocytes regulates cell migration and depresses TNF-alpha. We found the percentage of monocytes associated with disease activity in our study. This may be due to the synthesis and secretion of cytokines by monocytes [27].

Additionally, an essential proinflammatory cytokine IL-17 is secreted by neutrophils [29]. Specifically, IL-17 is involved in the recruitment and activation of neutrophils and monocytes, contributing to disease activity.

There are some limitations in this study. Firstly, we did not note immune suppressive drugs and biologic agents. Secondly, we did not study STEAP4, neutrophil extracellular traps, and proinflammatory cytokines. Thirdly, the present study was performed as retrospective.

In conclusion, the major finding in this study NLR and PLR are good indicators to assess the disease activity in RA. Similarly, NLR and PLR are associated with disease activity in RA. Similarly, NLR and PLR are good indicators to assess the disease activity in RA.

Scientific Responsibility Statement

The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing of some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.

Conflict of interest

None of the authors received any type of financial support that could be considered potential conflict of interest regarding the manuscript or its submission.

References

1. Assayag D, Lee JS, King TE Jr. Rheumatoid arthritis associated interstitial lung disease: a review. Medicina (B Aires). 2014; 74: 158–65.

2. Willemze A, Toes RE, Huizinga TW, Trouw LA. New biomarkers in rheumatoid arthritis. Neth J Med. 2012; 70: 392–9.

3. Karimifar M, Salesi M, Farajzadegan Z. The association of anti-CCP1 antibodies with disease activity score 28 (DAS-28) in rheumatoid arthritis. Adv Biomed Res. 2012; 1: 6. doi: 10.4103/2277-9175.98156

4. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocaña A et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106. doi: 10.1158/1055-9965.EPI-14-0146

5. Sahin S, Sankaya S, Alçelik A, Erdem A, Tasliyurt T, Akyol L, et al. Neutrophil-to-lymphocyte ratio is a useful predictor of atrial fibrillation in patients with diabetes mellitus. Acta Medica Mediterranea. 2013; 29: 847–51.

6. Yao Y, Simard AR, Shi FD, Hao J. IL-10-producing lymphocytes in inflammatory disease. Int Rev Immunol. 2013; 32: 324–36. doi: 10.3109/08830185.2012.762361.

7. Scapini P, Cassatella MA. Social net working of human neutrophils with in the immune system. Blood. 2014; 124: 710–9. doi: 10.1182/blood-2014-03-545217

8. Choi JL, Li S, Han JY. Platelet function tests: a review of progresses in clinical application. Biomed Res Int. 2014; 2014: 456569. doi: 10.1155/2014/456569.

9. Yazici S, Yazici M, Erer B, Erer B, Calik Y, Ozturk MA et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008; 75: 291–4.

10. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008; 75: 291–4.

11. Muddathir ARM, Haj FEJ. Platelet indices in sudanese patients with rheumatoid arthritis. Asian J Biomed Pharm Sci. 2013; 3: 1–3.

12. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005; 23: 93–9.

13. De Jong Z, van der Heijde D, McKenna SP, Whalley D, Oosterman J, van der Heijde D et al. Structural and functional assessment of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol. 1997; 36: 876–83.

14. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress and documentation. J Rheumatol. 2003; 30: 167–78.

15. Wang J, Arase H. Regulation of immune responses by neutrophils. Annals of the New York Academy of Sciences. 2014; 1319: 66–81.
Nlr and Plr are reliable marker in rheumatoid arthritis

16. Mc Ardle A, Flatley B, Pennington SR, FitzGerald O. Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. Arthritis research & therapy. 2015; 17:141.

17. Jallon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, Mantovani A. Neutrophils in innate and adaptive immunity. In Seminars in immunopathology. 2013; 35: 377-94.

18. Symmons DP, Farr M, Salmon M, Bacon PA. Lymphopenia in rheumatoid arthritis. Journal of the Royal Society of Medicine. 1989; 82: 462.

19. Boilard E, Blanco P, Nigrovic PA. Platelets: active players in the pathogenesis of arthritis and SLE. Nature Reviews Rheumatology. 2012; 8: 534. Doi: 10.1038/nrrheum.2012.

20. Uslu A U, Küçük A, Şahin A, Ugan Y, Yılmaz R, Güngör T et al. Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. International journal of rheumatic diseases, 2015;18: 731-5.

21. Kilic E, Rezvani A, Toprak AE, Erman H, Ayhan S K., Poyraz E et al. Evaluation of neutrophil to lymphocyte and platelet to lymphocyte ratios in rheumatoid arthritis. Dicle Medical Journal. 2016; 45: 241-7.

22. Tekeoğlu I, Gürol G, Harman H, Karakece E, Çiftçi I H. Overlooked hematological markers of disease activity in rheumatoid arthritis. International journal of rheumatic diseases. 2016; 19: 1078-82.

23. Chang B, Kwon O, Hong S, Lee CK, Yoo B, Kim YG. Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy. Modern rheumatology, 2017; 27: 405-10.

24. Rigby WF, Lampi K, Love JM, Furst DE. Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. International journal of rheumatology. 2017. Doi: 10.1155/2017/9614241.

25. Koiwa M, Goto S, Takahashi K, Kamada T, Takai S, Nakamura H. Neutrophil/ Lymphocyte Ratio in Patients with Rheumatoid Arthritis Treated with Biological Agents. Journal of Niigata Medical School. 2016; 83: 118-24.

26. Gasparian AY, Ayvazyan L, Mikhailidis DP, Kitas DG. Mean platelet volume: a link between thrombosis and inflammation? Current pharmaceutical design. 2011; 17: 47-58.

27. Tanaka Y, Matsumoto I, Iwanami K, Inoue A, Minami R, Umeda N et al. Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is a tumor necrosis factor alpha-induced protein that regulates IL-6, IL-8, and cell proliferation in synovium from patients with rheumatoid arthritis. Modern rheumatology. 2012; 22: 128-36.

28. Chowdhury CS, Giaglis S, Walker UA, Buser A, Hahn S, Hasler P. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis research & therapy. 2014; 16: R122. Doi: /10.1186/ar4579.

29. Katayama M, Ohmura , Yukawa N, Terao C, Hashimoto M, Yoshifugi H et al. Neutrophils are essential as a source of IL-17 in the effector phase of arthritis. PloS One. 2013; Doi:10.1371/journal.pone.0062231.

How to cite this article:
Şaş S. Neutrophil/lymphocyte and platelet/lymphocyte ratios are associated with disease activity in rheumatoid arthritis. J Clin Anal Med 2019;10(3): 379-83.